{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:34:31Z","timestamp":1792132471208,"version":"4.4.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0008854","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000}}],"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bill & Melinda Gates Foundation, United States Agency for International Development, and UK aid","award":["OPP1053230"],"award-info":[{"award-number":["OPP1053230"]}]},{"name":"Australian National Health and Medical Research Council","award":["1109035"],"award-info":[{"award-number":["1109035"]}]},{"name":"Australian National University Master of Applied Epidemiology Program"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>The Global Programme to Eliminate Lymphatic Filariasis has made considerable progress but is experiencing challenges in meeting targets in some countries. Recent World Health Organization guidelines have recommended two rounds of triple-drug therapy with ivermectin, diethylcarbamazine (DEC), and albendazole (IDA), in areas where mass drug administration (MDA) results with two drugs (DEC and albendazole) have been suboptimal, as is the case in Samoa. In August 2018, Samoa was the first country in the world to implement countrywide triple-drug MDA. This paper aims to describe Samoa\u2019s experience with program coverage and adverse events (AEs) in the first round of triple-drug MDA. We conducted a large cross-sectional community survey to assess MDA awareness, reach, compliance, coverage and AEs in September\/October 2018, 7\u201311 weeks after the first round of triple-drug MDA. In our sample of 4420 people aged \u22652 years (2.2% of the population), age-adjusted estimates indicated that 89.0% of the eligible population were offered MDA, 83.9% of the eligible population took MDA (program coverage), and 80.2% of the total population took MDA (epidemiological coverage). Overall, 83.8% (2986\/3563) reported that they did not feel unwell at all after taking MDA. Mild AEs (feeling unwell but able to do normal everyday things) were reported by 13.3% (476\/3563) and moderate or severe AEs (feeling unwell and being unable to do normal everyday activities such as going to work or school) by 2.9% (103\/3563) of participants. This study following the 2018 triple-drug MDA in Samoa demonstrated a high reported program awareness and reach of 90.8% and 89.0%, respectively. Age-adjusted program coverage of 83.9% of the total population showed that MDA was well accepted and well tolerated by the community.<\/jats:p>","DOI":"10.1371\/journal.pntd.0008854","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T14:07:23Z","timestamp":1606745243000},"page":"e0008854","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2508-412X","authenticated-orcid":true,"given":"Gabriela A.","family":"Willis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-4324","authenticated-orcid":false,"given":"Helen J.","family":"Mayfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-7572","authenticated-orcid":true,"given":"Therese","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Take","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-8039","authenticated-orcid":true,"given":"Katherine","family":"Gass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5215-3901","authenticated-orcid":true,"given":"Patricia M.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-4169","authenticated-orcid":true,"given":"Colleen L.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"pntd.0008854.ref001","author":"World Health Organization","year":"2018","journal-title":"Fact sheet: lymphatic filariasis [Internet]."},{"key":"pntd.0008854.ref002","volume-title":"Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers","author":"World Health Organization","year":"2006"},{"issue":"6","key":"pntd.0008854.ref003","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2471\/BLT.06.031047","article-title":"Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature","volume":"85","author":"S Wynd","year":"2007","journal-title":"Bull World Health Organ"},{"issue":"1","key":"pntd.0008854.ref004","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1371\/journal.pntd.0001479","article-title":"A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis","volume":"6","author":"K Gass","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0008854.ref005","doi-asserted-by":"crossref","first-page":"e3319","DOI":"10.1371\/journal.pntd.0003319","article-title":"Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease","volume":"8","author":"KD Ramaiah","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"issue":"RR-16","key":"pntd.0008854.ref006","first-page":"1","article-title":"Recommendations of the International Task Force for Disease Eradication","volume":"42","year":"1993","journal-title":"MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports \/ Centers for Disease Control"},{"key":"pntd.0008854.ref007","first-page":"25","article-title":"Elimination of lymphatic filariasis: current perspectives on mass drug administration","volume":"9","author":"JO Gyapong","year":"2018","journal-title":"Res Rep Trop Med"},{"issue":"94","key":"pntd.0008854.ref008","first-page":"457","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2018","volume":"41","author":"World Health Organization","year":"2019","journal-title":"Weekly epidemiological record"},{"key":"pntd.0008854.ref009","author":"World Health Organization","year":"2018","journal-title":"Samoa rolls out triple drug therapy to accelerate elimination of lymphatic filariasis"},{"issue":"1","key":"pntd.0008854.ref010","doi-asserted-by":"crossref","first-page":"e0005163","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa","volume":"11","author":"PU Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"pntd.0008854.ref011","article-title":"World Health Organization- Department of Control of Neglected Tropical Diseases","year":"2017","journal-title":"Guideline\u2013Alternative mass drug administration regimens to eliminate lymphatic filariasis: WHO"},{"key":"pntd.0008854.ref012","author":"Samoa Ministry of Health","year":"2017","journal-title":"National Action Plan to Eliminate Lymphatic Filariasis in Samoa, 2018\u20132024"},{"key":"pntd.0008854.ref013","volume-title":"Monitoring drug coverage for preventative chemotherapy","author":"World Health Organization","year":"2010"},{"issue":"Suppl 1","key":"pntd.0008854.ref014","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.actatropica.2010.08.021","article-title":"Improving community participation to eliminate lymphatic filariasis in American Samoa","volume":"120","author":"JD King","year":"2011","journal-title":"Acta Trop"},{"key":"pntd.0008854.ref015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41182-017-0063-8","article-title":"Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration","volume":"45","author":"SP Coutts","year":"2017","journal-title":"Trop Med Health"},{"key":"pntd.0008854.ref016","author":"World Health Organization","year":"2019","journal-title":"Preventive Chemotherapy: tools for improving the quality of reported data and information: a field manual for implementation: World Health Organization"},{"issue":"5","key":"pntd.0008854.ref017","doi-asserted-by":"crossref","first-page":"e0006454","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"PJ Budge","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"pntd.0008854.ref018","volume-title":"2016 Census projection [Internet]","author":"Samoa Bureau of Statistics","year":"2018"},{"key":"pntd.0008854.ref019","author":"Samoa Bureau of Statistics","year":"2018","journal-title":"2016 Census [Internet]"},{"key":"pntd.0008854.ref020","author":"Samoa Bureau of Statistics","year":"2019","journal-title":"Population and demography [Internet]"},{"issue":"2","key":"pntd.0008854.ref021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/0970-0218.96095","article-title":"Mass drug administration coverage evaluation survey for lymphatic filariasis in bagalkot and gulbarga districts","volume":"37","author":"PK Patel","year":"2012","journal-title":"Indian J Community Med"},{"key":"pntd.0008854.ref022","first-page":"12","article-title":"Exploratory study investigating factors influencing mass drug administration (MDA) compliance for lymphatic filariasis in Samoa","volume":"3","author":"H Joseph","year":"2010","journal-title":"Samoa Med J"},{"issue":"6","key":"pntd.0008854.ref023","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study","volume":"16","author":"GJ Weil","year":"2019","journal-title":"PLoS Med."},{"issue":"3","key":"pntd.0008854.ref024","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"19","key":"pntd.0008854.ref025","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"The New England journal of medicine"},{"issue":"5","key":"pntd.0008854.ref026","doi-asserted-by":"crossref","first-page":"e0007325","DOI":"10.1371\/journal.pntd.0007325","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Cote d'Ivoire","volume":"13","author":"C Edi","year":"2019","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0008854","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0008854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T15:02:25Z","timestamp":1607612545000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0008854"}},"subtitle":[],"editor":[{"given":"Marc P.","family":"H\u00fcbner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0008854","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.21.20072363","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}